Emu Oil Combined with Lyprinol™ Reduces Small Intestinal Damage in a Rat Model of Chemotherapy-Induced Mucositis

Nutr Cancer. 2016 Oct;68(7):1171-80. doi: 10.1080/01635581.2016.1208829. Epub 2016 Aug 11.

Abstract

Chemotherapy-induced mucositis is characterized by inflammation and ulcerating lesions lining the alimentary tract. Emu Oil and Lyprinol™ have independently demonstrated their therapeutic potential in intestinal inflammatory disorders, including mucositis. We investigated Emu Oil and Lyprinol™ in combination for their further potential to alleviate chemotherapy-induced mucositis in rats. Rats were gavaged with (1 ml) water, Olive Oil, Emu Oil + Olive Oil, Lyprinol™ + Olive Oil or Emu Oil + Lyprinol™ from Days 0 to 7, injected with saline (control) or 5-Fluorouracil (5-FU) on Day 5 and euthanized on Day 8. Myeloperoxidase (MPO) activity (indicative of acute inflammation), histological severity scores, and intestinal architecture were quantified. Myeloperoxidase activity was significantly increased in the jejunum and ileum following 5-FU, compared to saline controls. Both Olive Oil and Emu Oil + Lyprinol™ significantly reduced jejunal MPO levels (1.8-fold and 1.7-fold, respectively), whereas only Emu Oil + Lyprinol™ significantly decreased ileal MPO levels, relative to 5-FU controls. All oil treatments decreased histological severity scores in the jejunum and ileum, and normalized crypt depth in the mid small intestine, relative to 5-FU controls. Emu Oil combined with Lyprinol™ partially reduced acute small intestinal inflammation. Isolating bioactive constituents of these naturally sourced oils could provide a more targeted strategy to protect against intestinal mucositis.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / chemistry
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Antimetabolites, Antineoplastic / adverse effects*
  • Biomarkers / blood
  • Biomarkers / metabolism
  • Dasyproctidae
  • Dietary Supplements* / analysis
  • Enteritis / chemically induced
  • Enteritis / immunology
  • Enteritis / metabolism
  • Enteritis / prevention & control*
  • Female
  • Fluorouracil / adverse effects*
  • Gastrointestinal Agents / chemistry
  • Gastrointestinal Agents / therapeutic use
  • Ileum / drug effects
  • Ileum / immunology
  • Ileum / metabolism
  • Ileum / pathology
  • Intestinal Mucosa / drug effects
  • Intestinal Mucosa / immunology
  • Intestinal Mucosa / metabolism
  • Intestinal Mucosa / pathology
  • Jejunum / drug effects
  • Jejunum / immunology
  • Jejunum / metabolism
  • Jejunum / pathology
  • Lipids / chemistry
  • Lipids / therapeutic use*
  • Mucositis / chemically induced
  • Mucositis / immunology
  • Mucositis / metabolism
  • Mucositis / prevention & control*
  • Oils / chemistry
  • Oils / therapeutic use*
  • Olive Oil / chemistry
  • Olive Oil / therapeutic use
  • Organ Size / drug effects
  • Protective Agents / chemistry
  • Protective Agents / therapeutic use
  • Random Allocation

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antimetabolites, Antineoplastic
  • Biomarkers
  • Gastrointestinal Agents
  • Lipids
  • Oils
  • Olive Oil
  • Protective Agents
  • lyprinol
  • emu Oil
  • Fluorouracil